Sanofi - GSK Vaccine Candidate Boosts Other COVID-19 Vaccines

Paris-based Sanofi and GSK announced today that a single booster dose of their recombinant, adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses during the VAT0002 clinical trial.

The Sanofi - GSK booster vaccine showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson & Johnson, Moderna, Pfizer/BioNTech).

And the booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines.

Furthermore, the ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB).

During its last review, the DSMB identified no safety concerns.

To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.

“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received,” said Thomas Triomphe, EVP, Sanofi Pasteur, in a press release issued on December 15, 2021. 

These vaccine development efforts are supported by U.S. federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.